Ron van Schaik

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8073733/publications.pdf

Version: 2024-02-01

59 papers	3,774 citations	159585 30 h-index	138484 58 g-index
62 all docs	62 docs citations	62 times ranked	4965 citing authors

#	Article	IF	Citations
1	Pharmacogenetics: From Bench to Byteâ€" An Update of Guidelines. Clinical Pharmacology and Therapeutics, 2011, 89, 662-673.	4.7	869
2	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	2.0	374
3	Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. British Journal of Clinical Pharmacology, 2006, 61, 148-154.	2.4	200
4	Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics Journal, 2009, 9, 242-247.	2.0	198
5	Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in Î²-Blocker Users. Clinical Pharmacology and Therapeutics, 2009, 85, 45-50.	4.7	130
6	A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotypeâ€Based With Bodyâ€Weightâ€Based Tacrolimus Dosing After Living Donor Kidney Transplantation. American Journal of Transplantation, 2016, 16, 2085-2096.	4.7	129
7	Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes. Journal of the National Cancer Institute, 2004, 96, 1585-1592.	6.3	113
8	Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus. Clinical Pharmacology and Therapeutics, 2008, 83, 288-292.	4.7	113
9	UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients. Clinical Pharmacology and Therapeutics, 2009, 86, 319-327.	4.7	112
10	Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 555-565.	3.3	106
11	The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thrombosis and Haemostasis, 2004, 92, 61-66.	3.4	89
12	Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. Journal of Antimicrobial Chemotherapy, 2007, 60, 1104-1107.	3.0	78
13	Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2021, 23, 1047-1064.	2.8	73
14	Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662. Clinical Pharmacology and Therapeutics, 2014, 96, 81-89.	4.7	67
15	Covariates of tramadol disposition in the first months of life. British Journal of Anaesthesia, 2008, 100, 525-532.	3.4	60
16	The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. British Journal of Cancer, 2010, 103, 765-771.	6.4	56
17	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. British Journal of Clinical Pharmacology, 2019, 85, 601-615.	2.4	56
18	C-kit Asp-816-Val Mutation Analysis in Patients with Mastocytosis. Dermatology, 2007, 214, 15-20.	2.1	52

#	Article	IF	Citations
19	The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Pharmacogenetics and Genomics, 2017, 27, 313-322.	1.5	52
20	CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Research and Treatment, 2013, 140, 363-373.	2.5	43
21	Circulating Free Insulin-Like Growth Factor (IGF)-I , Total IGF-I, and IGF Binding Protein-3 Levels Do Not Predict the Future Risk to Develop Prostate Cancer: Results of a Case-Control Study Involving 201 Patients within a Population-Based Screening with a 4-Year Interval. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4391-4396.	3.6	42
22	Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Molecular Psychiatry, 2008, 13, 597-605.	7.9	42
23	Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leukemia Research, 2010, 34, 154-159.	0.8	40
24	User considerations in assessing pharmacogenomic tests and their clinical support tools. Npj Genomic Medicine, 2018, 3, 26.	3.8	38
25	Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Polymorphism and Aortic Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 771-776.	2.4	35
26	The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics Journal, 2010, 10, 219-225.	2.0	35
27	Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics Journal, 2013, 13, 251-256.	2.0	35
28	Effects of CYP Induction by Rifampicin on Tamoxifen Exposure. Clinical Pharmacology and Therapeutics, 2012, 92, 62-67.	4.7	34
29	Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. British Journal of Cancer, 2000, 82, 112-117.	6.4	33
30	Personalized laboratory medicine: a patient-centered future approach. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1981-1991.	2.3	33
31	Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period. Clinical Pharmacology and Therapeutics, 2009, 85, 379-386.	4.7	32
32	Androgen receptor (AR) splice variant 7 and fullâ€length AR expression is associated with clinical outcome: a translational study in patients with castrateâ€resistant prostate cancer. BJU International, 2019, 124, 693-700.	2.5	32
33	The 5-HT_{2C} receptor gene Cys23Ser polymorphism influences the intravaginal ejaculation latency time in Dutch Caucasian men with lifelong premature ejaculation. Asian Journal of Andrology, 2014, 16, 607.	1.6	31
34	CYP2C9*2 Allele Increases Risk for Hypoglycemia in POR*1/*1 Type 2 Diabetic Patients Treated with Sulfonylureas. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, 60-63.	1.2	30
35	Expression of activin and inhibin subunits, receptors and binding proteins in Human adrenocortical neoplasms. Clinical Endocrinology, 2006, 65, 792-799.	2.4	27
36	Clinical Impact of New Prostate-Specific Antigen WHO Standardization on Biopsy Rates and Cancer Detection. Clinical Chemistry, 2008, 54, 1999-2006.	3.2	26

#	Article	IF	Citations
37	CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Research and Treatment, 2013, 139, 649-655.	2.5	21
38	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treatment Reviews, 2022, 104, 102340.	7.7	21
39	Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics Journal, 2016, 16, 54-59.	2.0	20
40	What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? â€“ Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. Clinica Chimica Acta, 2021, 520, 168-171.	1.1	20
41	Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. European Journal of Endocrinology, 2014, 170, 181-191.	3.7	19
42	Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. Pharmacogenomics Journal, 2016, 16, 519-524.	2.0	17
43	Subclinical hypocalcaemia in captive Asian elephants (Elephas maximus). Veterinary Record, 2008, 162, 475-479.	0.3	16
44	Pharmacogenetics in Immunosuppressive Therapy. Therapeutic Drug Monitoring, 2004, 26, 343-346.	2.0	14
45	Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice. Frontiers in Pharmacology, 2021, 12, 640032.	3.5	14
46	5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. Bone, 2012, 50, 1260-1265.	2.9	13
47	Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer and Prostatic Diseases, 2015, 18, 167-172.	3.9	12
48	Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?. Annals of Oncology, 2017, 28, 183.	1.2	12
49	Considerations for the development of a reference method for sequencing of haploid DNA â€“ an opinion paper on behalf of the IFCC Committee on Molecular Diagnostics. International Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1343-50.	2.3	9
50	Doubt About the Feasibility of Preemptive Genotyping. Clinical Pharmacology and Therapeutics, 2013, 93, 233-233.	4.7	9
51	Association of CYP3A variants with kidney transplant outcomes. Renal Failure, 2015, 37, 562-566.	2.1	9
52	Genetic Techniques for Pharmacogenetic Analyses. Current Pharmaceutical Design, 2010, 16, 231-237.	1.9	8
53	Implementation of a companion diagnostic in the clinical laboratory: The BRAF example in melanoma. Clinica Chimica Acta, 2015, 439, 128-136.	1.1	5
54	CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. Pharmacogenomics, 2017, 18, 613-620.	1.3	5

#	Article	IF	Citations
55	Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. Thorax, 2021, 76, 1150-1153.	5.6	4
56	Increased liver enzyme levels during azathioprine treatment: beware of concomitant use of proton pump inhibitors. British Journal of Dermatology, 2015, 173, 1338-1339.	1.5	3
57	High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report. Pharmacogenomics, 2019, 20, 567-570.	1.3	3
58	Cytochrome P450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. Pharmacogenomics, 2018, 19, 1097-1099.	1.3	0
59	Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.. Blood, 2009, 114, 2208-2208.	1.4	0